Fig. 3: Deletion of Trp53 in MSCs prevents the hematopoietic toxicity of MDM2i.

A Schematic view of the experiment design. B Bar graph showing white blood cell (WBC) counts in indicated mice after the last dose of treatment. Data points represent the WBC count in each mouse, (mean ± SD); ***P < 0.0001, **P < 0.01, Student’s t test. C Representative microscopic view of H&E staining of BM sections isolated from indicated mice after the last dose of treatment. The right panels display higher magnification. D High magnification view of H&E staining of BM sections in C showing the distribution of megakaryocytes. E Quantification of the megakaryocytes from D (controls n = 3; Osx-Mdm2fl/+ n = 4; Osx-Trp53fl/fl n = 3; Vav-Trp53fl/fl n = 3); ****P < 0.0001, **P < 0.01, Student’s t test.